320 related articles for article (PubMed ID: 32156778)
1. Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.
Sun L; Li CW; Chung EM; Yang R; Kim YS; Park AH; Lai YJ; Yang Y; Wang YH; Liu J; Qiu Y; Khoo KH; Yao J; Hsu JL; Cha JH; Chan LC; Hsu JM; Lee HH; Yoo SS; Hung MC
Cancer Res; 2020 Jun; 80(11):2298-2310. PubMed ID: 32156778
[TBL] [Abstract][Full Text] [Related]
2. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
Li CW; Lim SO; Xia W; Lee HH; Chan LC; Kuo CW; Khoo KH; Chang SS; Cha JH; Kim T; Hsu JL; Wu Y; Hsu JM; Yamaguchi H; Ding Q; Wang Y; Yao J; Lee CC; Wu HJ; Sahin AA; Allison JP; Yu D; Hortobagyi GN; Hung MC
Nat Commun; 2016 Aug; 7():12632. PubMed ID: 27572267
[TBL] [Abstract][Full Text] [Related]
3. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation.
Wang M; Wang J; Wang R; Jiao S; Wang S; Zhang J; Zhang M
Commun Biol; 2019; 2():392. PubMed ID: 31667366
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.
De Sousa Linhares A; Battin C; Jutz S; Leitner J; Hafner C; Tobias J; Wiedermann U; Kundi M; Zlabinger GJ; Grabmeier-Pfistershammer K; Steinberger P
Sci Rep; 2019 Aug; 9(1):11472. PubMed ID: 31391510
[TBL] [Abstract][Full Text] [Related]
5. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
[TBL] [Abstract][Full Text] [Related]
6. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
Front Immunol; 2020; 11():895. PubMed ID: 32528470
[TBL] [Abstract][Full Text] [Related]
7. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
Tan S; Zhang H; Chai Y; Song H; Tong Z; Wang Q; Qi J; Wong G; Zhu X; Liu WJ; Gao S; Wang Z; Shi Y; Yang F; Gao GF; Yan J
Nat Commun; 2017 Feb; 8():14369. PubMed ID: 28165004
[TBL] [Abstract][Full Text] [Related]
8. In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction.
Lu CH; Chung WM; Tsai CH; Cheng JC; Hsu KC; Tzeng HE
Sci Rep; 2022 Jan; 12(1):303. PubMed ID: 34996924
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics.
Kumar D; Mishra A; Lisok A; Kureshi R; Shelake S; Plyku D; Sen R; Doucet M; De Silva RA; Mease RC; Forde PM; Jaffee EM; Desai P; Ganguly S; Gabrielson E; Vaidya D; Spangler JB; Nimmagadda S
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34508005
[TBL] [Abstract][Full Text] [Related]
10. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 Pathway in Breast Cancer.
Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
[TBL] [Abstract][Full Text] [Related]
12. N-glycosylation of PD-1 promotes binding of camrelizumab.
Liu K; Tan S; Jin W; Guan J; Wang Q; Sun H; Qi J; Yan J; Chai Y; Wang Z; Deng C; Gao GF
EMBO Rep; 2020 Dec; 21(12):e51444. PubMed ID: 33063473
[TBL] [Abstract][Full Text] [Related]
13. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
Li CW; Lim SO; Chung EM; Kim YS; Park AH; Yao J; Cha JH; Xia W; Chan LC; Kim T; Chang SS; Lee HH; Chou CK; Liu YL; Yeh HC; Perillo EP; Dunn AK; Kuo CW; Khoo KH; Hsu JL; Wu Y; Hsu JM; Yamaguchi H; Huang TH; Sahin AA; Hortobagyi GN; Yoo SS; Hung MC
Cancer Cell; 2018 Feb; 33(2):187-201.e10. PubMed ID: 29438695
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
15. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
17. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Yang WH; Cha JH; Xia W; Lee HH; Chan LC; Wang YN; Hsu JL; Ren G; Hung MC
Cancer Res; 2018 Jul; 78(14):3761-3768. PubMed ID: 29789418
[TBL] [Abstract][Full Text] [Related]
18. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
19. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
Kamimura N; Wolf AM; Iwai Y
J Nippon Med Sch; 2019; 86(1):10-14. PubMed ID: 30918149
[TBL] [Abstract][Full Text] [Related]
20. In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.
Zhai W; Zhou X; Du J; Gao Y
Methods Enzymol; 2019; 629():361-381. PubMed ID: 31727249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
